Valeant Pharmaceuticals Intl Inc. Has No Friends

Nobody likes Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), and that could spell big trouble for the company.

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has never been a particularly well-liked company. But over the past six weeks, the company has made some new enemies.

Now it seems that everyone has their sights set on Valeant, whether it be regulators, politicians, health insurance providers, or short sellers. And any one of them could do significant damage to the company and its stock price. We take a look at each in turn below.

The regulators

Two weeks ago, two U.S. prosecutors—one from Massachusetts and the other from Manhattan—subpoenaed Valeant. They are investigating the company’s pricing strategies and patient-assistance programs.

Then on Monday, in the midst of Valeant’s current troubles, the company said it was subpoenaed by the U.S. Department of Justice (DoJ) back in mid-September. The DoJ subpoena was related to payments made and agreements between its Bausch & Lomb division and medical professionals.

Valeant clearly wanted to bury this news, only disclosing it six weeks after the fact (without issuing a press release) at a time when there were other headlines surrounding the company. So, you should expect more headlines to come from this investigation, especially since the DoJ is involved. That won’t be good for the stock price.

The politicians

In response to the recent uproar over drug-price increases, Democratic presidential candidates Hillary Clinton and Bernie Sanders are proposing sweeping reforms to bring costs back down. This includes importing more lower-cost drugs from Canada, as well as having Medicare negotiate its own discounted rates. That would, of course, be bad news for Valeant.

Republicans haven’t been silent on the issue either. Presidential candidate Marco Rubio said that some companies were engaged in “pure profiteering.” Polls show that Americans are sick of high drug costs, and this attitude crosses party lines. Eventually, you may see more action from the U.S. government.

Health insurance providers

Thanks to recent revelations about Philidor, it’s starting to look like Valeant is ripping off health insurance providers. It also looks like Valeant was using a complex structure to hide its actions.

Health insurance providers will not be amused and may refuse to offer some of Valeant’s drugs, at least in cases where a competing drug (or generic) is available. Once again, that would put a big dent in the company’s bottom line.

Short sellers

To be clear, Valeant’s troubles are not caused by short sellers such as Citron’s Andrew Left. But the short sellers have made Valeant’s headaches a lot worse.

They have done a lot of investigative work (especially John Hempton at Bronte Capital) and have brought to light a lot of the issues surrounding Valeant. They have also contributed to Valeant’s stock price declines (especially Andrew Left), which inhibits the company’s ability to make more acquisitions.

No friends

Even the pharmaceutical industry’s chief lobby, PhRMA, has thrown Valeant under the bus. The organization said that Valeant’s strategy is “more reflective of a hedge fund than an innovative biopharmaceutical company.”

So, at this point, there is a massive bullseye on Valeant, and a number of different people are aiming straight for that target. Investors should stay very far away.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »